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ABSTRACT
 
Objectives:
 
To evaluate the cost-effectiveness and budget
impact of a new heat wrap therapy for low back pain
compared to paracetamol and ibuprofen from the per-
spective of the UK National Health Service (NHS).
Methods: We evaluated cost-effectiveness using data
from a phase III trial comparing the three therapies in 371
patients aged 18 to 55 years presenting with acute
uncomplicated low back pain. The primary effectiveness
measure used was successful treatment, deﬁned as both
clinically meaningful pain relief and clinically meaningful
reduction in disability. We conducted a simple evaluation
using NHS prescription costs and a modeled extrapola-
tion including the costs of further treatment and consul-
tations for patients treated unsuccessfully or with adverse
events. Uncertainty was addressed using nonparametric
bootstrapping and sensitivity analyses.
Results: Successful treatment was reported by 57% of
patients treated with heat wrap therapy, 26% treated with
paracetamol and 18% treated with ibuprofen (P < 0.05
for heat wrap vs. both other groups). NHS prescription
cost per patient was estimated to be £1.35 for heat wrap
therapy, £0.26 for paracetamol, and £0.28 for ibuprofen
and cost per successful treatment was £3.52 for heat wrap
therapy compared to paracetamol, and £2.72 compared
to ibuprofen. In the modeled extrapolation, NHS cost per
patient was £27.77 for heat wrap therapy, £34.20 for
paracetamol, and £36.04 for ibuprofen. Sensitivity anal-
yses indicated that the ﬁndings were robust to plausible
changes in data and assumptions.
Conclusions: Economic evaluation of this study suggests
that the NHS cost of introducing heat wrap therapy in
place of oral analgesics would be modest and heat wrap
therapy might potentially reduce the total cost of manag-
ing episodes of lower back pain.
Keywords: budget impact, cost-effectiveness, heat ther-
apy, low back pain, UK drug tariff.
 
Introduction
 
Approximately 40% of UK adults report suffering
from back pain in the course of 1 year, of which
15% report being in pain throughout the year, the
remainder reporting shorter periods [1]. The prev-
alence of back pain varies by age group, peaking in
adults aged 45 to 64 years, with lower frequency
reported in both younger and older adults [1].
Although not life-threatening and often self-limit-
ing, low back pain is a substantial cause of morbid-
ity and impairs quality of life. Quality of life
assessed by the EuroQoL 5-item quality of life
assessment questionnaire (the EQ-5D) in patients
with low back pain presenting to the general prac-
titioner (GP) is estimated to be in the range 0.62 to
0.67 on a utility scale of 0 to 1 [2], substantially
lower than age-matched population norms [3].
Although individual episodes are brief, the eco-
nomic impact of back pain, including the consulta-
tion with GPs, physiotherapy, radiology, and
prescription drug use [4], was estimated to be £1.6
billion in the UK in 1998 [1,4,5]. Cost to the
National Health Service (NHS) was estimated to be
£1.1 billion and the remainder was funded by pri-
vate sector insurers or by patients themselves. In the
same survey, the annual cost of work loss due to
back pain was estimated to be in the range of £5.0
billion to £10.7 billion [4].
In the UK, the Royal College of General Practi-
tioners (RCGP) [6] issues guidelines for the man-
agement of acute low back pain. These guidelines
recommend that patients presenting to the GP with
acute low back pain should be managed initially
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with diagnostic triage to exclude nerve root
pain and serious spinal pathology. For patients
with acute and uncomplicated low back pain,
recommended initial therapy is to remain active,
combined with symptomatic measures. The most
commonly used treatments for symptomatic relief
are oral analgesics, e.g., nonsteroidal anti-
inﬂammatory drugs (NSAIDs) [7], although
application of ice or heat is also recommended.
Referral to physiotherapy is recommended if oral
analgesics are ineffective in relieving pain and
restoring normal functional status [6].
Survey data suggest that the guidelines are
broadly followed. Of patients with low back pain
consulting GPs, 61% to 68% receive a prescription,
and the most commonly prescribed drugs for back
pain are oral analgesics such as ibuprofen, coprox-
amol, or cocodamol [7–10]. Other therapies
reported include topical creams or sprays [8]. Top-
ical heat is an alternative, and effective therapy,
relaxing tight muscles and providing pain relief.
Unfortunately, common methods of delivering heat,
such as hot water bottles and electric heating pads,
are inconvenient and may restrict patient mobility:
immobility is itself detrimental to recovery from
back pain [11].
A new therapeutic heat wrap therapy (Therma-
Care
 
®
 
 Procter & Gamble Ltd.) has been developed
for use for low back pain. It is a single-use device suit-
able for use in a GP setting that provides at least
8 hours of continuous, consistent low-level heat at
40
 
∞
 
C, by means of controlled iron oxidation, is suit-
able to be worn under clothing, and does not restrict
patient mobility. It has been shown to be effective
and safe for acute uncomplicated low back pain
compared to a placebo in pilot clinical trials and sub-
sequently in a large phase III clinical trial. Therma-
Care has achieved regulatory approval for marketing
as a Class IIa medical device in the European Union.
The UK NHS is a cash-constrained system in
which resources are limited, so the potential beneﬁts
of therapy must be seen in the context of the effect
on prescription costs and GP workloads. Because
low back pain is a very common condition, the
potential impact on the NHS of introducing new
treatments may be substantial. It is therefore appro-
priate to assess whether new interventions for low
back pain offer sufﬁcient beneﬁt to justify the
expenditure of scarce NHS resources.
The objective of this study was to evaluate the
cost-effectiveness in the UK of low-level heat wrap
therapy in the management of acute uncomplicated
low back pain, in comparison with the standard
practice of oral analgesics.
 
Methods
 
Study Design
 
We evaluated the likely costs and beneﬁts of Ther-
maCare from the perspective of the UK NHS. We
performed a simple cost-effectiveness evaluation
using prescription cost to the NHS and the effec-
tiveness of the therapeutic heat wrap using data
from the pivotal study comparing therapeutic heat
wrap with paracetamol and ibuprofen [12]. We fur-
ther constructed a cost-effectiveness model to esti-
mate the potential impact of the therapeutic heat
wrap on the overall management of acute uncom-
plicated low back pain, including the costs of GP
consultations and referral to physiotherapy. We
ﬁnally made an estimate of the likely budget impact
of introducing the therapeutic heat wrap product
into general prescription use in the NHS.
 
Simple Cost-Effectiveness Evaluation
 
Effectiveness data used in this evaluation were
taken from the pivotal trial reported by Nadler et al.
[12]. A total of 371 adult patients, aged 18 to
55 years, who had presented with acute, uncompli-
cated, muscular, nontraumatic, nonspeciﬁc low
back pain of moderate or greater intensity, were
included in the study. Patients with severe underly-
ing morbidity or sciatica and other secondary
causes of low back pain were excluded. Patients
were asked to refrain from taking usual analgesic
medication and were randomized to receive 2 days’
treatment with either 8 hours of heat wrap therapy
(n 
 
=
 
 113), paracetamol at 2 
 
¥
 
 500 mg four times
daily (n 
 
=
 
 113), or ibuprofen 2 
 
¥
 
 200 mg three
times daily (n 
 
=
 
 106). Two small control groups,
oral placebo (n 
 
=
 
 20) and unheated back wrap
(n 
 
=
 
 19), were included to maintain blinding. In
addition, the investigator remained blinded
throughout the duration of the study. Patients were
followed up on day 4.
The primary end point of the study was day 1
mean pain relief. The patient assessed pain relief on
a 6-point numerical rating scale (NRS), hourly for
8 hours on day 1, every 2 hours on day 2, and once
on each of days 3 and 4 (Fig. 1). Secondary efﬁcacy
end points included disability, lateral trunk ﬂexibil-
ity, and muscle stiffness. Disability was assessed at
baseline and on days 2 and 4 using the Roland-
Morris Disability Questionnaire (RMDQ) rated on
a 0 to 24 scale [13].
On each of the four days, mean pain relief was
signiﬁcantly higher with heat wrap therapy than
with either comparator (
 
P
 
 
 
<
 
 0.001). Disability,
assessed on day 4, was reduced to a signiﬁcantly
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greater extent with heat wrap therapy compared to
either of the other two treatments (
 
P
 
 
 
<
 
 0.01). A
number of other secondary effectiveness parameters
showed signiﬁcant improvement.
Noncompliance with the study protocol was
reported in six patients (one randomized to the heat
wrap, two to paracetamol, and three to ibuprofen).
All patients for whom effectiveness measures were
recorded at baseline and for whom at least one
other observation was available were, however,
included in this evaluation. Full details of the meth-
odology and conduct of the trial are presented
elsewhere [12].
No adverse events reported in the study were
serious although systemic adverse events were
reported in 10.4% of the ibuprofen group, 6.2% of
the heat wrap group, and 4.4% of the paracetamol
group (statistical differences not noted). For costing
purposes we included only events considered by the
investigators to be probably or possibly related to
treatment. These events occurred in 4.7% of the
patients treated with ibuprofen, 1.8% of the heat
wrap therapy group, and 2.7% of the paracetamol-
treated group.
The primary efﬁcacy end point for the economic
evaluation was the percentage of “successfully
treated patients.” Successful treatment was deﬁned
as both clinically meaningful pain relief and clini-
cally meaningful reduction in disability, because the
main goals of pain management are to reduce pain
and to reduce the level of disability in daily life [14].
We were not able to locate a published assess-
ment of clinically meaningful improvements for a 6-
point NRS for pain relief. Nevertheless, a 2-point
improvement has been found to be clinically rele-
vant both in a 5-point pain relief NRS and in an 11-
point NRS for pain intensity [15,16]. Clinically
meaningful pain relief was therefore deﬁned as a 2-
point improvement in the 6-point NRS. Clinically
meaningful reduction in disability was deﬁned as a
2-point improvement or better on the 24-point
RMDQ, following the deﬁnition suggested by the
questionnaire’s designers [17]. Patients were consid-
ered to be successfully treated if they experienced
clinically meaningful pain relief on at least three of
the four days observed in the study and also
reported a clinically meaningful reduction in disa-
bility from baseline at day 4. Patient-level data were
reanalyzed to calculate the proportion of patients
successfully treated in each of the active treatment
groups.
The simple cost-effectiveness evaluation included
the cost of each prescription, calculated as the basic
NHS price of the treatment, plus the dispensing
charge, corrected for patient contribution [18].
NHS prices for ibuprofen and paracetamol were
taken from published sources [19]. At the time of
writing, the therapeutic heat wrap is not yet avail-
able in the UK, and the price used is the manufac-
turer’s estimate.
In the UK NHS, nonexempt patients make a ﬂat
rate payment (the “prescription charge”) of £6.20
 
Figure 1
 
Mean pain relief  scores at different time points. Error bars show 
 
±
 
 one standard error.
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per  item  dispensed  [20].  For  all  three  treatments,
the cost to the patient of buying the item over-the-
counter (OTC) would be less than £6.20. We have
assumed that nonexempt patients will purchase
these items OTC rather than paying the prescription
charge, resulting in zero cost to the NHS. This is a
conservative assumption: if nonexempt patients pay
the prescription charge, the NHS would make a net
proﬁt.
Many UK patients are, however, exempt from
prescription charges and make no payment for NHS
prescriptions. We assumed that exempt patients
would have their prescriptions dispensed through
the NHS. We estimated that 24% of prescriptions
for this population would be written for exempt
patients, calculated as the percentage of prescrip-
tions exempt from charges in the UK population
aged 18 to 55 years. The estimate of the percentage
of people exempt from prescription charges was
varied in the sensitivity analysis.
All costs were estimated from the NHS perspec-
tive using standard published sources (see Table 1)
[21].
We calculated cost-effectiveness ratios by divid-
ing the mean NHS prescription cost per patient by
the proportion of patients successfully treated to
calculate the NHS prescription cost per successfully
treated patient. Incremental cost-effectiveness ratios
(ICERs) were calculated as the difference in mean
NHS prescription cost per patient between thera-
pies divided by the difference in the proportion of
patients successfully treated.
Sensitivity tests performed included varying the
deﬁnition of treatment success and varying the pro-
portion of patients exempt from prescription
charges. Conﬁdence intervals around the percentage
of successfully treated patients, alternative deﬁni-
tions of successful treatment, and between-group
differences in these values were calculated using
nonparametric bootstrapping [22]. We also deﬁned
a “worst case” scenario, in which the national rate
of free prescriptions of 85% was used [18].
 
Cost-Effectiveness Model
 
A decision tree (Fig. 2) was constructed to describe
the management of an episode of low back pain,
 
Table 1
 
Unit costs and sources
 
Item Unit cost Source
GP consultation £16.00  [21]
Prescription charge (per item) £6.20  [18]
Cost per physiotherapy, average episode of  5.2 hours patient contact £185.00  [21]
Dispensing/prescription preparation cost £0.95  [18]
Heat wrap, six pack £13.99 Manufacturer
Heat wrap, cost per treatment course (two wraps) £4.66 Calculated
Ibuprofen 84 
 
¥ 
 
200 mg pack £1.69  [19]
Ibuprofen, cost per treatment course (2 days, 400 mg tid) £0.24 Calculated
Paracetamol 20 
 
¥ 
 
500 mg pack £0.15  [19]
Paracetamol, cost per treatment course (2 days, 1000 mg qid) £0.12 Calculated
 
Abbreviations: Qid, four times daily; tid, three times daily.
 
Figure 2
 
Decision tree for treatment of  low back pain (LBP). NSAID, nonsteroidal anti-inﬂammatory drug.
Successfully treated
Refer to physiotherapy 
Treat with NSAID
Reconsults GP
Does not reconsult
Not successfully treated
Adverse event
Heat wrap therapy
Paracetamol
 [+] 
Ibuprofen
 [+] 
Consults GP for acute
uncomplicated LBP
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including therapies recommended by the guidelines
of the RCGP [6].
Patients enter the model at the time of ﬁrst con-
sultation for acute uncomplicated low back pain.
We compare three possible treatment choices: heat
wrap therapy, paracetamol, and ibuprofen. After
each treatment, the patient may be successfully
treated, not successfully treated, or experience an
adverse event:
1. Patients successfully treated exit the model.
2. Patients who experience adverse events return
for one additional GP visit to manage the event.
3. Patients not successfully treated may reconsult
their GP, or may choose not to do so, and those
who  reconsult  may  receive  treatment  with
an  NSAID  (assumed  to  be  the  least  cost
option, paracetamol), or may be referred to
physiotherapy.
The proportion of patients successfully treated
and free of adverse events was taken from the sim-
ple cost-effectiveness model above. The proportion
of unsuccessfully treated individuals who return for
an additional GP consultation was estimated as
50%. This ﬁgure causes the model to estimate over-
all reconsultation of 40% after initial consultation
for low back pain, which matches UK survey data
[8]. The likelihood of physiotherapy referral for
patients who return after unsuccessful initial ther-
apy was estimated as 18%. This ﬁgure causes the
model to estimate the number of people receiving
physiotherapy annually for low back pain to be
around 330,000, the lower end of estimates of the
annual number of NHS-ﬁnanced referrals to physi-
otherapy for low back pain [1,23]. The cost of
referral  used  is  that  of  one  typical  “episode”
of physiotherapy, consisting of a mean of 5.2 hours
of care [21].
Costs included in the modeled extrapolation
from the trial included the cost of the initial GP con-
sultation for low back pain, costs of repeat consul-
tations, and cost of physiotherapy referrals. These
costs were used to calculate the total NHS cost of
managing an episode of acute uncomplicated low
back pain. Cost-effectiveness ratios were calculated
in the same manner as for the simple cost-effective-
ness analysis, and the outcome measure used was
total NHS cost per successfully treated patient.
Sensitivity analyses used for the simple evalua-
tion were repeated for the modeled extrapolation.
Additional sensitivity tests explored the effect of the
following changes to the inputs of the model: vary-
ing the rate of reconsultation after adverse events,
removing physiotherapy referral—a “worst case”
analysis, removing all costs other than the initial
prescription, and with the percentage of exempt
prescriptions set at 85%.
 
Budget Impact Assessment
 
We estimated the number of patients aged 18 to
55 years receiving a prescription for an NSAID in
primary. The UK population of 18- to 55-year-olds
is 33.1 million [24], in whom the prevalence of low
back pain is 40% [1]. Each year 39% of low back
pain sufferers consult their GP [1], leading to an
estimate  of  5.2  million  total  GP  consultations
for low back pain (calculated as 33.1
million 
 
¥
 
 40% 
 
¥
 
 39%). Acute uncomplicated low
back pain is estimated to account for 66% of GP
consultations for low back pain [25] and 68% of
GP consultations for low back pain result in a pre-
scription [7]. The number of prescriptions for acute
uncomplicated low back pain issued annually was
estimated to be 2.3 million (calculated as 5.2
million 
 
¥
 
 66% 
 
¥
 
 68%).
We estimated the budget impact of introducing
the therapeutic heat wrap by combining the esti-
mated prevalence of acute uncomplicated low back
pain with the estimated total NHS cost of treatment
per patient. Additional data inputs were made to
estimate the budget impact: current prescriptions
for acute low back pain were estimated to be split
equally between paracetamol and ibuprofen; heat
wrap therapy was estimated to be prescribed for
20% of patients, divided equally between those
who would have received paracetamol or ibupro-
fen. The same sensitivity analyses were conducted
as in the modeled evaluation.
 
Results
 
Simple Cost-Effectiveness Evaluation
 
Of the 371 patients in the intent-to-treat popula-
tion, we excluded 39 patients from this analysis
(10.5%) in the small control groups and 9 patients
(2.4%) for whom no data were available for either
pain relief or disability. Effectiveness data were eval-
uable for 323 patients, 112 in the heat wrap group,
108 in the paracetamol group, and 103 in the ibu-
profen group.
Using the base case deﬁnition of treatment suc-
cess, the percentage of patients successfully treated
was 57% (95% conﬁdence interval by bootstrap-
ping: 47–66%) with therapeutic heat wrap, 26%
(20–37%) with paracetamol, and 18% (9–24%)
with ibuprofen (both ibuprofen and paracetamol
 
P
 
 
 
<
 
 0.05 compared with the therapeutic heat wrap).
The between-group differences in the proportion of
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patients successfully treated were robust to different
deﬁnitions of success—in each scenario heat wrap
therapy showed a statistically signiﬁcant higher rate
of success than either of the other treatments
(Table 2).
Costs and cost-effectiveness results are presented
in Table 3. Including the dispensing fee and allow-
ing for patients exempt from prescription charges,
the NHS prescription cost per patient would be
£1.35 for heat wrap therapy, £0.26 for paraceta-
mol, and £0.28 for ibuprofen. The additional cost
of treatment with heat wrap therapy is £1.09 per
treated patient compared to paracetamol and £1.06
compared to ibuprofen.
NHS prescription cost per successfully treated
patient was £2.37 in the heat wrap group, £1.00 in
the paracetamol group, and £1.55 in the ibuprofen
group. ICERs were £3.52 for the comparison
between the therapeutic heat wrap and paraceta-
mol, and £2.72 for the comparison between the
therapeutic heat wrap and ibuprofen.
In the “worst case” sensitivity analysis (85% of
prescriptions exempt), the additional cost of heat
wrap therapy was £3.86 versus paracetamol and
£3.76 versus ibuprofen, and the incremental costs
per successful treatment with heat wrap therapy
was £12.46 versus paracetamol and £9.64 versus
ibuprofen. Other sensitivity tests included varying
the deﬁnition of success used, varying the cost of
physiotherapy within published limits, testing con-
ﬁdence limits around the percentage of patients suc-
cessfully treated, and including costs for all and for
none of the adverse events in the clinical study. The
results of these tests all indicated that the heat wrap
was less costly and more effective than either para-
cetamol or ibuprofen.
 
Cost-Effectiveness Model
 
Including the costs of GP visits, reconsultation, and
physiotherapy, the per patient cost of managing an
episode of acute uncomplicated low back pain with
heat wrap therapy was £27.77, with paracetamol
£34.20, and with ibuprofen £36.04 (see Table 4). A
further analysis using the lowest recommended dos-
ages of ibuprofen (600 mg/day) and paracetamol
(2 g/day) and assuming similar efﬁcacy and a 50%
reduction in adverse events maintained the domi-
nance in favor of heat wrap therapy.
Therapeutic heat wrap was more expensive than
NSAIDs in two tests. When only the drug/device
cost and initial GP consultation were included, the
incremental cost-effectiveness of heat wrap was esti-
mated to be £3.06 per successfully treated patient
compared to paracetamol, and £1.51 per success-
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fully treated patient compared to ibuprofen. In
our “worst case” scenario (85% free prescriptions
and ignoring all costs apart from the drug/device
and initial GP contact), the incremental cost-
effectiveness of heat wrap was estimated to be
£12.00 per successfully treated patient compared to
paracetamol, and £8.43 per successfully treated
patient compared to ibuprofen.
 
Budget Impact Assessment
 
In the base case scenario, using costs and effective-
ness from the modeled extrapolation, heat wrap
therapy would result in a cost saving to the NHS of
£3.4 million per year (Table 5). This saving includes
the cost savings implications of the occurrence of
85,000 fewer GP consultations and 14,000 fewer
physiotherapy referrals.
Using the same set of sensitivity analyses as the
modeled extrapolation, the savings to the NHS
ranged from £0.9 million to £3.8 million. In the
conservative scenario, where only the drug/device
cost and initial GP consultation were included, the
increase in NHS expenditure resulting from the
introduction of the therapeutic heat wrap was £0.3
million per year. In the “worst case” scenario the
additional NHS costs were estimated to be £2.4
million per year.
 
Discussion
 
Clinical data were taken from a large randomized
clinical trial for uncomplicated acute low back
pain comparing therapeutic heat wrap with ibu-
profen and paracetamol. The objective of this trial
was to compare the efﬁcacy of continuous low-
level heat wrap therapy with that of ibuprofen
and paracetamol in subjects with acute nonspe-
ciﬁc low back pain. Evaluations of economic
 
Table 3
 
Costs and effectiveness of  treatment—simple model
 
Treatment group
Heat wrap (HW)
(n 
 
=
 
 112)
Paracetamol (P)
(n 
 
=
 
 108)
Ibuprofen (I)
(n 
 
=
 
 103)
Increment
(HW-P)
Increment
(HW-I)
Mean values
Proportion successfully treated 0.57 0.26 0.18 0.31 0.39
Cost of  prescription (item plus dispensing charge) £5.61 £1.07 £1.19 £4.54 £4.42
 
Base case
 
Twenty-four percent of  patients exempt from prescription charge
NHS prescription cost per patient (after correcting for patient
payment)
£1.35 £0.26 £0.28 £1.09 £1.06
NHS prescription cost per successfully treated patient £2.37 £1.00 £1.56
Incremental cost-effectiveness ratio (ICER) £3.52* £2.72*
Sensitivity test
Eighty-ﬁve percent of  patients exempt from prescription charge
NHS prescription cost per patient (after correcting for patient
payment)
4.77 0.91 1.01 £3.86 £3.76
NHS prescription cost per successfully treated patient £8.37 £3.50 £5.62
ICER £12.46* £9.64*
 
*Calculated as difference in cost divided by difference in effect.
 
Table 4
 
Cost-effectiveness model for three therapies for low back pain: cohort of  1000 patients
 
Heat wrap
(HW)
Paracetamol
(P)
Ibuprofen
(I)
Increment
(HW-P)
Increment
(HW-I)
Treatment outcomes
Successfully treated patients  570  260  180 310 390
Adverse events  18  27  47
 
-
 
9
 
-
 
29
Patient reconsultation  224  383  434
 
-
 
159
 
-
 
210
Treatment events
GP consultations 1,224 1,383 1,434
 
-
 
159
 
-
 
210
Courses of  physiotherapy  37  64  69
 
-
 
27
 
-
 
32
Prescriptions for initial drug/device 1,000 1,000 1,000   0   0
Prescriptions for second line NSAID  169  293  318 -124 -149
Treatment costs
GP consultations £19,582 £22,132 £22,937 –£2,551 –£3,356
Courses of  physiotherapy £6,797 £11,762 £12,740 –£4,965 –£5,943
Prescriptions for initial drug/device £1,346 £256 £285 £1,090 £1,061
Prescriptions for second line NSAID £43 £75 £81 –£32 –£38
Total cost £27,768 £34,225 £36,044 –£6,457 –£8,276
Per patient cost £27.77 £34.22 £36.04 –£6.46 –£8.28
Cost per person successfully treated £48.72 £131.63 £200.24 Dominant Dominant
 
Abbreviation: NSAID, nonsteroidal anti-inﬂammatory drug.
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beneﬁts were not included in the study and there-
fore no pharmacoeconomic parameters were
measured. To perform this analysis, original data
from the clinical trial were reanalyzed to generate
a measure of successful treatment by combining
patient-level data on pain relief and reduction in
disability. Although this deﬁnition of success was
not prospectively deﬁned, the deﬁnitions of clini-
cally meaningful improvement are supported in
the literature [15–17] and sensitivity analyses
showed the data to be robust to the deﬁnition of
treatment success used.
The study comprised 2 days’ treatment followed
by an additional 2 days of follow-up. The primary
analysis reported here was based on data collected
on day 4. This time point was selected to make
maximum use of the data collected in the study, and
to evaluate whether differences between therapies
were transitory or would persist after therapy was
withdrawn. We found that the difference between
heat wrap therapy and both ibuprofen and para-
cetamol was maintained after the end of therapy.
Sensitivity analysis assessed the impact of assessing
only up to day 2, and found results consistent with
the main evaluation.
A Cochrane review by Tulder et al. [26] reports
relative risk of pain reduction with NSAIDs at
1 week compared to placebo, based on six trials
using a variety of proxies to indicate improvement.
Rates of successful treatment for the ibuprofen and
paracetamol arms of this study are based on a def-
inition of success that was more aggressive than that
reported in the Cochrane review (improvement
within 2 or 4 days), and success rates are therefore
lower.
The model was sensitive to the percentage of
patients exempt from prescription charges: increas-
ing this percentage from our base case 24% to 85%
materially altered the results. The prevalence of low
back pain peaks in working age adults [1] who are
generally required to pay prescription charges, and
the study on which our evaluation was based was
limited to adults aged 18 to 55 years. For these rea-
sons we assumed that the working age population
will use the therapeutic heat wrap predominantly.
The sensitivity analysis using 85% as the rate of free
prescriptions was included as a “worst case” sce-
nario, and is felt to be unrealistically pessimistic.
Even in the “worst case” analyses, the incremental
cost of heat wrap appears to be modest and the
cost-effectiveness ratios are low.
We generated a simple decision-analytic model to
explore the potential beneﬁts if improved treatment
of low back pain results in fewer patients returning
for further treatment. The results indicate, using a
wide range of assumptions, that improved treat-
ment would offer material resource savings to the
NHS. The link between more successful treatment
and reduced rates of reconsultation is, however, not
yet supported by direct evidence. The model has
also not attempted to take account of likelihood of
low back pain recurrence nor its potential budget
impact.
In addition to cost-effectiveness ratios, the poten-
tial impact on the NHS budget is an important fac-
tor inﬂuencing the rate of uptake of new
interventions in the UK. The NHS is a tax-funded
health care system operating within a ﬁxed budget,
so a new intervention that results in material new
spending will require resources to be reallocated
 
Table 5
 
Estimated budget impact of  introducing heat wrap therapy in England and Wales
 
% of
patients
Number of
patients
Successfully
treated patients
Adverse
events
GP
reconsultations
Physiotherapy
referrals Cost
Per patient data (results of
cost-effectiveness model)
Heat wrap therapy 0.57 0.02 0.22 0.037 £27.77
Paracetamol 0.26 0.03 0.38 0.064 £34.22
Ibuprofen 0.18 0.05 0.43 0.069 £36.04
Budget impact in England and
Wales
If  no heat wrap therapy available
No. receiving heat wrap therapy 0 0  0  0  0  0 £0
No. receiving paracetamol 50 1,157,907 301,056 30,741 443,796 73,615 £39.6 million
No. receiving Ibuprofen 50 1,157,907 208,423 54,618 502,051 79,742 £41.7 million
Total 2,315,813 509,479 85,359 945,847 153,358 £81.4 million
If  heat wrap therapy available
No. receiving heat wrap therapy 20  463,163 264,003 8,198 103,679 17,017 £12.9 million
No. receiving paracetamol 40  926,325 240,845 24,593 355,037 58,892 £31.7 million
No. receiving Ibuprofen 40  926,325 166,739 43,695 401,641 63,794 £33.4 million
Total 2,315,813 671,586 76,485 860,356 139,703 £78.0 million
Impact of  heat wrap therapy 162,107
 
-
 
8,874
 
-
 
85,491
 
-
 
13,655 –£3.4 million
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from elsewhere in the organization. Our analysis
suggests  that  the  impact  of  therapeutic  heat  wrap
on total NHS spending would be modest, and if the
modeled reductions in reconsultation rate take
place, use of the therapeutic heat wrap may result in
resource gains for the NHS.
The results indicate, using a wide range of
assumptions, that heat wrap therapy offers material
resource savings to the NHS. Although encourag-
ing, these ﬁndings are tentative however. This anal-
ysis is based on results from one small randomized
controlled trial designed for regulatory purposes
[27]. Furthermore, the link between successful
treatment and reduced rates of reconsultation is not
yet supported by direct evidence. Further research,
demonstrating reduced rates of reconsultation after
therapeutic heat wrap therapy, could further
strengthen the cost-effectiveness case for its use.
This study included costs from the perspective of
the NHS alone. Back pain is a major reason for lost
workdays in the UK, and thus imposes substantial
costs on employers and on sufferers that are not
reﬂected in NHS costs [1]. Nevertheless, productiv-
ity costs were not collected in the study. The impact
of the heat wrap therapy in the workplace has been
investigated in an exploratory workplace study
among manual workers with acute low back pain
[28]. The results of this study showed that the use of
the heat wrap therapy led to improved productivity.
 
Conclusions
 
In this study, continuous heat wrap therapy resulted
in a larger percentage of patients being successfully
treated compared to paracetamol and ibuprofen.
Economic evaluation suggests that the NHS cost of
introducing heat wrap therapy in place of oral treat-
ments would be modest. If the increased effective-
ness of heat wrap therapy leads to a reduction in GP
or physiotherapy consultations, then heat wrap
therapy is likely to lead to a net saving of resources
for the UK NHS.
 
This analysis was funded by a grant from Procter & Gam-
ble Health Sciences Institute.
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